Argenx stock: Goldman Sachs keeps EUR 959.00 target for Argenx stock

Published on 10/19/2026 at 16:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BofA lifted its target to USD 1,157 on October 12, 2026. Argenx stock costs EUR 726.40 on October 19, 2026, minus 0.22 percent versus the Xetra close.

Analyst targets remain central

Goldman Sachs maintained a Buy rating and a EUR 959.00 target on October 16, 2026.
BofA raised its target to USD 1,157 from USD 1,136 on October 12, 2026.
Argenx stock costs EUR 726.40 at Lang & Schwarz on October 19, 2026 at 4:00 p.m. CEST, minus 0.22 percent versus the Xetra close of October 16, 2026.
Argenx trades at a price-to-earnings ratio of 31.29.

Bauhaus-Grafikposter: IgG-Antikörper als geometrisches Y-Symbol in Primärfarben Rot Blau Gelb Schwarz auf weißem Grund, konstruktivistischer Stil der 1920er Jahre — Argenx NL0010832176 IgG-Antikörper als Y-förmiges Bauhaus-Poster in roten blauen und gelben Primärfarben, Illustration mit AI erstellt.

Goldman Sachs maintained a Buy rating and a EUR 959.00 target for Argenx on October 16, 2026, according to Markets Insider. The target lies 32.02 percent above the EUR 726.40 price. Argenx stock was trading at EUR 726.40 at Lang & Schwarz on October 19, 2026 at 4:00 p.m. CEST, minus 0.22 percent versus the Xetra close of October 16, 2026 at EUR 728.00.

BofA target reaches USD 1,157

Bank of America raised its Argenx target to USD 1,157 from USD 1,136 on October 12, 2026, while keeping a Buy rating, Markets Insider reported. The firm also modeled third-quarter VYVGART revenue of USD 1.63 billion in its preview. The target updates leave analyst valuation well above the euro quotation, but the currencies are not directly interchangeable.

Price position and range

The primary-market reference for Argenx was USD 814.69 at 2:02 p.m. UTC on October 19, 2026, with a USD 819.14 previous close. Its 52-week USD range was USD 661.85 to USD 1,072.75, while the market capitalization stood at USD 51.1 billion. The latest euro quotation sits inside that wider dollar range after the company shares fell to the lower end of recent trading levels earlier in October.

Valuation and company scale

Argenx had a price-to-earnings ratio of 31.29 on October 19, 2026, and no dividend yield was reported. Financial statements show second-quarter 2026 revenue of USD 1.542 billion, consolidated net income of USD 472.0 million and diluted earnings per share of USD 7.32. The company develops immunology therapies, with VYVGART as its leading commercial product.

Comparison with peers

Argenx: minus 0.22 percent, P/E 31.29, market capitalization USD 51.1 billion.

UCB (Euronext Brussels, EUR): plus 0.10 percent, P/E 17.77, market capitalization EUR 39.0 billion.

Vertex Pharmaceuticals (Nasdaq, USD): plus 0.40 percent, P/E 29.19, market capitalization USD 127.2 billion.

What the targets imply

The analyst targets provide the clearest valuation reference for the session, while the peer figures show a higher earnings multiple for Argenx than UCB and a slightly higher multiple than Vertex Pharmaceuticals. The next important company-specific marker is the next published financial update, with the investor-relations calendar listing financial reports and events for shareholders.

The further course of trading is shown by the continuously updated real-time quote of Argenx stock.